Published in Circulation on July 30, 2002
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest (2005) 8.58
Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol (2007) 2.84
Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques. Circ Res (2007) 2.74
Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol (2006) 2.70
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol (2005) 2.38
Macrophage roles following myocardial infarction. Int J Cardiol (2008) 2.14
CSF-1 signaling mediates recovery from acute kidney injury. J Clin Invest (2012) 1.98
Critical roles of macrophages in the formation of intracranial aneurysm. Stroke (2010) 1.85
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J (2011) 1.70
Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J Clin Invest (2009) 1.28
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol (2010) 1.12
Emerging role of mast cells and macrophages in cardiovascular and metabolic diseases. Endocr Rev (2012) 1.11
Roles of macrophages in flow-induced outward vascular remodeling. J Cereb Blood Flow Metab (2008) 1.05
Macrophages heterogeneity in atherosclerosis - implications for therapy. J Cell Mol Med (2010) 1.05
Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. J Clin Invest (2004) 1.02
Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol (2011) 0.92
Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1. Circulation (2012) 0.91
Recent advances in drug eluting stents. Int J Pharm (2012) 0.91
Nanoparticulate carriers for the treatment of coronary restenosis. Int J Nanomedicine (2007) 0.90
Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J (2015) 0.90
Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J (2008) 0.88
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics (2015) 0.87
Myocardial regenerative properties of macrophage populations and stem cells. J Cardiovasc Transl Res (2012) 0.87
Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis. Theranostics (2014) 0.87
Treatment with chondroitinase ABC alleviates bleomycin-induced pulmonary fibrosis. Med Mol Morphol (2007) 0.86
Macrophage-derived IL-18 and increased fibrinogen deposition are age-related inflammatory signatures of vascular remodeling. Am J Physiol Heart Circ Physiol (2014) 0.85
Cyclooxygenase-2 in endothelial and vascular smooth muscle cells restrains atherogenesis in hyperlipidemic mice. Circulation (2014) 0.84
Clodronate-containing liposomes attenuate lung injury in rats with severe acute pancreatitis. J Zhejiang Univ Sci B (2010) 0.84
LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. J Clin Invest (2015) 0.82
Innate immunity has a dual effect on vascular healing: suppression and aggravation of neointimal formation and remodeling post-endotoxin challenge. Atherosclerosis (2007) 0.81
The investigation of macrophage infiltration in the early phase of ischemic acute renal failure in mice. Korean J Intern Med (2008) 0.81
Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int (2013) 0.81
Current advances in the translation of vascular tissue engineering to the treatment of pediatric congenital heart disease. Yale J Biol Med (2012) 0.80
Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J (2010) 0.80
Clodronate-superparamagnetic iron oxide-containing liposomes attenuate renal injury in rats with severe acute pancreatitis. J Zhejiang Univ Sci B (2014) 0.79
CD11c+ Dendritic Cells Accelerate the Rejection of Older Cardiac Transplants via Interleukin-17A. Circulation (2015) 0.79
Macrophages are required for host survival in experimental urogenital schistosomiasis. FASEB J (2014) 0.78
Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr (2008) 0.78
Enhanced biocompatibility of CD47-functionalized vascular stents. Biomaterials (2016) 0.78
Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med (2012) 0.78
Targeted anti-inflammatory systemic therapy for restenosis: the Biorest Liposomal Alendronate with Stenting sTudy (BLAST)-a double blind, randomized clinical trial. Am Heart J (2012) 0.77
Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics (2014) 0.77
Differential effect of zoledronic acid on human vascular smooth muscle cells. J Surg Res (2012) 0.77
Predicting in vivo efficacy of potential restenosis therapies by cell culture studies: species-dependent susceptibility of vascular smooth muscle cells. Open Cardiovasc Med J (2008) 0.77
Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiol Open Access (2015) 0.77
Characterizing heterogeneity in the response of synovial mesenchymal progenitor cells to synovial macrophages in normal individuals and patients with osteoarthritis. J Inflamm (Lond) (2016) 0.77
Pharmacological modulation of cell death in atherosclerosis: a promising approach towards plaque stabilization? Br J Pharmacol (2011) 0.76
The heterogenic properties of monocytes/macrophages and neutrophils in inflammatory response in diabetes. Life Sci (2014) 0.76
Gastrointestinal tract and the mucosal macrophage reservoir in HIV infection. Clin Vaccine Immunol (2014) 0.76
Nanotechnology for the treatment of coronary in stent restenosis: a clinical perspective. Vasc Cell (2011) 0.76
Triptolide mitigates radiation-induced pulmonary fibrosis via inhibition of axis of alveolar macrophages-NOXes-ROS-myofibroblasts. Cancer Biol Ther (2016) 0.76
Fast-degrading bioresorbable arterial vascular graft with high cellular infiltration inhibits calcification of the graft. J Vasc Surg (2016) 0.75
Pleiotropic action of CpG-ODN on endothelium and macrophages attenuates angiogenesis through distinct pathways. Sci Rep (2016) 0.75
Rapid tissue regeneration induced by intracellular ATP delivery-A preliminary mechanistic study. PLoS One (2017) 0.75
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. Blood (2012) 2.57
Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene (2002) 1.96
Biochemical and molecular mechanisms of action of bisphosphonates. Bone (2010) 1.92
A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J Control Release (2008) 1.87
High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents. Proc Natl Acad Sci U S A (2008) 1.82
VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res (2003) 1.82
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol (2006) 1.67
Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release (2008) 1.66
Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A (2010) 1.64
Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release (2002) 1.58
RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A (2004) 1.52
Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol (2008) 1.51
Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch (2006) 1.49
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res (2004) 1.44
Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells. J Immunol (2013) 1.39
Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol (2002) 1.38
High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34
A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem J (2002) 1.33
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res (2004) 1.28
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol (2007) 1.23
miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med (2011) 1.21
Laminin-induced signaling in tumor cells. Cancer Lett (2005) 1.21
Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A (2010) 1.19
Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res (2006) 1.17
Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci (2008) 1.16
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis (2003) 1.13
MicroRNAs are associated with human embryo implantation defects. Hum Reprod (2011) 1.13
Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp Cell Res (2008) 1.12
Synthesis, Characterization, and Crystal Structure of Dicalcium Glutarylbis(phosphonate) Dihydrate: A Covalently Pillared Layer Structure with the Potential for Epitaxial Growth on Hydroxyapatite. Inorg Chem (1998) 1.12
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol (2008) 1.11
Transferrin mediated solid lipid nanoparticles containing curcumin: enhanced in vitro anticancer activity by induction of apoptosis. Int J Pharm (2010) 1.11
In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci U S A (2011) 1.10
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol (2012) 1.07
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis (2010) 1.04
The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol (2005) 1.03
Systemic depletion of macrophages by liposomal bisphosphonates reduces neointimal formation following balloon-injury in the rat carotid artery. J Cardiovasc Pharmacol (2003) 1.03
Delivery and expression of pDNA embedded in collagen matrices. J Control Release (2004) 1.03
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol (2006) 1.03
Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation (2003) 1.03
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat (2004) 1.01
A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem (2004) 1.00
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer (2006) 0.99
Activation of γδ T cells by bisphosphonates. Adv Exp Med Biol (2010) 0.99
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol (2012) 0.99
Zoledronic acid-induced IPP/ApppI production in vivo. Life Sci (2007) 0.98
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol (2004) 0.98
Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients. Cancer Immunol Immunother (2010) 0.97
Indirect stimulation of human Vγ2Vδ2 T cells through alterations in isoprenoid metabolism. J Immunol (2011) 0.97
Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression. Mol Ther (2006) 0.95
Analysis of unstirred water layer in in vitro permeability experiments. J Pharm Sci (2009) 0.95
Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs (2008) 0.95
In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol (2005) 0.95
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol (2003) 0.94
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.94
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res (2003) 0.94
Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release (2006) 0.93
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement. Clin Cancer Res (2012) 0.93
Disrupted gene pattern in patients with repeated in vitro fertilization (IVF) failure. Hum Reprod (2009) 0.93
Mevalonate pathway intermediates downregulate zoledronic acid-induced isopentenyl pyrophosphate and ATP analog formation in human breast cancer cells. Biochem Pharmacol (2009) 0.92
Inhibition of mevalonate pathway is involved in alendronate-induced cell growth inhibition, but not in cytokine secretion from macrophages in vitro. Eur J Pharm Sci (2003) 0.91
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 0.91
Magnetic nanoparticles for targeted vascular delivery. IUBMB Life (2011) 0.91
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol (2013) 0.90
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev (2003) 0.90
Decreased levels of osteopontin and bone sialoprotein II are correlated with reduced proliferation, colony formation, and migration of GFP-MDA-MB-231 cells. Int J Oncol (2004) 0.90
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res (2008) 0.89
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer (2005) 0.89
Site-specific gene delivery to stented arteries using magnetically guided zinc oleate-based nanoparticles loaded with adenoviral vectors. FASEB J (2013) 0.89
Nanospheres of a bisphosphonate attenuate intimal hyperplasia. J Nanosci Nanotechnol (2006) 0.89
Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion (2005) 0.89
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol (2010) 0.88
Preparation of alendronate liposomes for enhanced stability and bioactivity: in vitro and in vivo characterization. AAPS J (2008) 0.88
Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem (2004) 0.88
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis (2004) 0.88
Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis (2002) 0.88
Modulation of NO and ROS production by AdiNOS transduced vascular cells through supplementation with L-Arg and BH4: implications for gene therapy of restenosis. Atherosclerosis (2013) 0.88
Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials (2005) 0.88
The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone (2009) 0.88
Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem (2003) 0.87
Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm (2006) 0.87